Our Story

​

TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans.

 

The TEGA pipeline includes two major programs: recombinant production of heparan sulfate and enzyme replacement therapy to treat genetic deficiencies in degradation of heparan sulfate.